Case Control Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jun 7, 2016; 22(21): 5050-5059
Published online Jun 7, 2016. doi: 10.3748/wjg.v22.i21.5050
Figure 1
Figure 1 Collection of twin pairs. IBD: Inflammatory bowel diseases; CD: Crohn’s disease; UC: Ulcerative colitis.
Figure 2
Figure 2 Figure shows fecal calprotectin measures stratified (A), harwey bradshaw index stratified by phenotype (B) and simple clinical colitis index stratified (C) by phenotype. IBD: Inflammatory bowel diseases; CD: Crohn’s disease; UC: Ulcerative colitis.
Figure 3
Figure 3 Figure shows how the collected twin data may be used in different downstream analyses. The figure illustrates the initial genetic concordance in liability, the progressive discordance for disease liability due to heterogeneous exposures, and the possible future concordance for IBD, but not necessarily for treatment. IBD: Inflammatory bowel diseases.